Eurovestech
164 Field End Road, Eastcote, Middlesex, HA5 1RH, United Kingdom
Overview
Eurovestech is the AIM listed pan-European development capital fund focused on high-technology enterprises. They pride themselves on the quality of their dealflow, the calibre of their co-investors and their strong network of professional contacts. Their directors and team have backgrounds in chartered accountancy, media and the high technology industry with companies such as Schroders, Compaq and Pearson.
- Total investments
- 2
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Finance
- Financial Services
- Venture Capital
Investment portfolio
- VizEat
Participated · Equity · Sep 2016
VizEat operates a marketplace that connects people seeking authentic local dining with hosts who cook and invite guests into their homes, and also offers cooking classes and local food tours. Founded in July 2014, the company says it has grown from 50 hosts to more than 20,000 across 110 countries. Most of its roughly 20 staff are located in Paris, and it also maintains offices in Spain and Italy. VizEat targets tourists and local residents in multicultural cities, and it partners with travel and hospitality providers to market experiences to business travelers to reduce seasonality. Recent moves include acquiring French pioneer Cookening last year and hiring Pierrine Griffiths to the management team. The company plans to use new funding to accelerate growth, open local offices, and recruit country managers in the U.K. and Germany.
- Tute Genomics
Led · Series A · Dec 2014
Tute Genomics offers a cloud-based genome interpretation platform that delivers analytics, interpretation and reporting for clinical sequencing to support predictive, preventive and precision medicine. The platform is positioned for healthcare use and aims to enable genomics-driven clinical decision-making. The company is led by Reid Robison, MD MBA (CEO) and Kai Wang, PhD (President and Chairman). Tute Genomics is based in Provo, Utah. The article reports the company recently closed a financing round (see deal details). No operating metrics were provided in the article. Tute Genomics has developed a comprehensive cloud-based genome analytics platform that helps clinicians and researchers draw meaningful insights from genome sequencing data. The company processes sequencing data in the cloud and has commercially deployed its platform across clinical labs, molecular diagnostic companies and research institutions. Nearly 10,000 samples have been processed on the platform to date. Tute plans to use the new funding to expedite genetic discoveries and enable the adoption of genomic medicine in everyday clinical care. The company is led by Reid Robison, MD MBA, CEO, and Kai Wang, PhD, President. Tute Genomics builds a cloud-based genome interpretation platform that uses proprietary machine-learning algorithms to rapidly prioritize clinically relevant genetic variants, genes and pathways. The platform supports discovery of novel disease genes and identification of predictive biomarkers. Its analysis now includes over 90 annotation types, scoring methods and genetic databases. The company is led by CEO Reid J. Robison, MD MBA, and President Dr. Kai Wang, and participated in the BoomStartup accelerator in Utah. Tute raised $1.5M in seed funding from a group of backers and additionally raised approximately $300K via AngelList's Syndicate. The company intends to use the funds to further develop its software.
Team
No current team members are available.